ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG

(EUZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176

01/10/2022 | 01:38pm EDT

DGAP-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Strategic Company Decision/Joint Venture
???????Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176

10-Jan-2022 / 19:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Berlin, 10 January 2022. Eckert & Ziegler Radiopharma GmbH (EZR), the radiopharmaceutical production arm of Eckert & Ziegler, has signed a joint venture and exclusive long-term supply agreements for Ytterbium-176 with Atom Mines LLC, an innovative producer of enriched Ytterbium isotopes and a subsidiary of the non-profit Pointsman Foundation, both based in Austin, Texas. Cancer therapies based on Lutetium-177 are proving highly effective, yet the world supply of the indispensable precursor, Ytterbium-176, has previously been measured in grams per year. A new technology partially financed by EZR and developed by Atom Mines now promises to overcome this bottleneck: first samples delivered met the relevant quality criteria, in particular isotope purity. This opens the way for EZR to make Lutetium-177 available in large quantities to pharmaceutical companies worldwide to treat hundreds of thousands of patients per year.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

 


Information and Explanation of the Issuer to this News:

While shown to be highly effective in clinical trials, regulatory approvals previously limited Lutetium-177 based radiotherapeutics to rare cancer types such as neuroendocrine tumours. Recently, however, the FDA and other regulatory bodies extended approvals for Lutetium-177 based radiotherapeutics to prostate cancer, the second leading cause of cancer death. This has raised supply chain concerns among pharmaceutical producers, in particular about the scarce supply of Ytterbium-176.

'We are excited about the achievements of the team at Atom Mines and the potential of their isotope separation technology', commented Lutz Helmke, COO of EZR. 'They have closed an important gap in the supply chain for Lutetium-177 nca which will enable EZR to strengthen its position as a partner of choice for global radiopharmaceutical companies such as Novartis, Bayer, or Telix.'

About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG with approx. 900 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives


10-Jan-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1266912

 
End of Announcement DGAP News Service

1266912  10-Jan-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1266912&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reports Earnings Results for the First..
CI
05/12Eckert & Ziegler with Sales Growth in the First Quarter of 2022
EQ
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reaffirms Earnings Guidance for the Ye..
CI
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
EQ
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
CI
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Report of the Supervisory Board
PU
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Proposal on the appropriation of net income
PU
04/11ECKERT & ZIEGLER : Hauck & Aufhauser remains its Buy rating
MD
04/11ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Hauck & Aufhäuser
PU
04/08ECKERT & ZIEGLER : Radboud University Medical Center Netherlands to Image First Patient wi..
EQ
More news
Analyst Recommendations on ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
More recommendations
Financials
Sales 2022 205 M 213 M 213 M
Net income 2022 30,7 M 31,9 M 31,9 M
Net cash 2022 55,7 M 57,9 M 57,9 M
P/E ratio 2022 28,0x
Yield 2022 1,20%
Capitalization 866 M 900 M 900 M
EV / Sales 2022 3,95x
EV / Sales 2023 3,80x
Nbr of Employees 866
Free-Float 67,1%
Chart ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Duration : Period :
Eckert & Ziegler Strahlen- und Medizintechnik AG Technical Analysis Chart | EUZ | DE0005659700 | MarketScreener
Technical analysis trends ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 41,70 €
Average target price 152,00 €
Spread / Average Target 265%
EPS Revisions
Managers and Directors
Andreas Eckert Chairman-Executive Board
Wolfgang Maennig Chairman-Supervisory Board
Helmut Grothe Vice Chairman-Supervisory Board
Albert Rupprecht Member-Supervisory Board
Edgar Löffler Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG-55.69%889
JOHNSON & JOHNSON3.38%465 363
PFIZER, INC.-15.46%280 096
ABBVIE INC.13.37%271 251
ELI LILLY AND COMPANY5.58%262 514
ROCHE HOLDING AG-15.85%258 421